Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642442 | 1.00 | TK1 (0.41) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2641583 | 1.00 | TK1 (0.41) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL23892079 | 1.00 | TK1 (0.41) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2888800 | 0.81 | TYMS (0.48) | — | |
| SCHEMBL31685733 | 0.79 | TK1 (0.32) | TK1LMNASMN1; SMN2 | |
| SCHEMBL346202 | 0.76 | POLA1 (0.42) | — | |
| 5-Bromouracil SCHEMBL4280022 | 0.76 | TK1 (0.40) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Fluorouracil SCHEMBL8778444 | 0.76 | LMNA (0.51) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL24420223 | 0.75 | TK1 (0.39) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL1675551 | 0.75 | TK1 (0.39) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | INTERCELL AG (AT) | 2011-12-08 | — | — | US | claimed |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | INTERCELL AG (AT) | 2011-09-29 | — | — | US | claimed |
| JP-4734241-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-2345420-A1 | Use of a TH1 immune response inducing adjuvant for enhancing immune responses | Intercell AG (AT) | 2011-07-20 | — | — | EP | claimed |
| EP-2313116-A1 | IMPROVED BACTERIAL POLYSACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS | Intercell AG (AT) | 2011-04-27 | — | — | EP | claimed |
| JP-4676426-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| EP-2275131-A2 | HCV Vaccines | Intercell AG (AT) | 2011-01-19 | — | — | EP | claimed |
| US-7858588-B2 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2010-12-28 | — | — | US | claimed |
| EP-1648502-B1 | HCV VACCINES | INTERCELL AG (AT) | 2010-12-01 | — | — | EP | claimed |
| US-20100297170-A1 | VACCINES | VALNEVA AUSTRIA GMBH (AT) | 2010-11-25 | — | — | US | claimed |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2004-12-09 | — | — | US | claimed |
| WO-2004084938-A1 | IMPROVED VACCINES | INTERCELL AG (AT) | 2004-10-07 | — | — | WO | claimed |
| EP-1450821-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | Intercell AG (AT) | 2004-09-01 | — | — | EP | claimed |
| EP-1390495-A2 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC MOLECULES | Intercell AG (AT) | 2004-02-25 | — | — | EP | claimed |
| EP-1296713-B1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL BIOMEDIZINISCHE FORSCHUNGS & ENTWICKLUNGS GMBH (AT) | 2003-09-17 | — | — | EP | claimed |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | VALNEVA AUSTRIA GMBH (AT) | 2003-09-11 | — | — | US | claimed |
| WO-2003047602-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL AG (AT) | 2003-06-12 | — | — | WO | claimed |
| EP-1296713-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | Cistem Biotechnologies GmbH (AT) | 2003-04-02 | — | — | EP | claimed |
| WO-2002095027-A2 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC MOLECULES | INTERCELL AG (AT) | 2002-11-28 | — | — | WO | claimed |
| WO-2001093905-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL BIOMEDIZINISCHE FORSCHUNGS- UND ENTWICKLUNGS AG (AT) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | HAVCR2, CXCR3, CD81 | TK1 2304/4885LMNA 4088/4885SMN1; SMN2 4718/4885 |
| US-20100297170-A1 | VACCINES | DDX1, DHX15, DDX5 | TK1 936/4885LMNA 2941/4885SMN1; SMN2 1647/4885 |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | NT5C3B, UMPS, NT5C2 | TK1 126/4885LMNA 1392/4885SMN1; SMN2 1322/4885 |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | DDOST, NGLY1, DAD1 | TK1 984/4885LMNA 3284/4885SMN1; SMN2 3248/4885 |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | NT5C3B, PNP, UMPS | TK1 91/4885LMNA 1559/4885SMN1; SMN2 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.